TRT01A,AETERM,AEBODSYS,param,value,sub_col_label,AETERM_ORD,AEBODSYS_ORD
Placebo,ANY BODY SYSTEM,ANY BODY SYSTEM,N,69,N_and_N_pct,1,1
Placebo,ANY BODY SYSTEM,ANY BODY SYSTEM,N_tot,301,AEs,1,1
Placebo,ANY BODY SYSTEM,ANY BODY SYSTEM,N_pct,0.8023255813953488,N_and_N_pct,1,1
Xanomeline High Dose,ANY BODY SYSTEM,ANY BODY SYSTEM,N,70,N_and_N_pct,1,1
Xanomeline High Dose,ANY BODY SYSTEM,ANY BODY SYSTEM,N_tot,436,AEs,1,1
Xanomeline High Dose,ANY BODY SYSTEM,ANY BODY SYSTEM,N_pct,0.9722222222222222,N_and_N_pct,1,1
Xanomeline Low Dose,ANY BODY SYSTEM,ANY BODY SYSTEM,N,86,N_and_N_pct,1,1
Xanomeline Low Dose,ANY BODY SYSTEM,ANY BODY SYSTEM,N_tot,454,AEs,1,1
Xanomeline Low Dose,ANY BODY SYSTEM,ANY BODY SYSTEM,N_pct,0.8958333333333334,N_and_N_pct,1,1
Placebo,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,142,5
Placebo,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,142,5
Placebo,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,142,5
Placebo,AGITATION,PSYCHIATRIC DISORDERS,N,2,N_and_N_pct,55,11
Placebo,AGITATION,PSYCHIATRIC DISORDERS,N_tot,2,AEs,55,11
Placebo,AGITATION,PSYCHIATRIC DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,55,11
Placebo,ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,231,3
Placebo,ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,1,AEs,231,3
Placebo,ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,231,3
Placebo,ANXIETY,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,144,11
Placebo,ANXIETY,PSYCHIATRIC DISORDERS,N_tot,2,AEs,144,11
Placebo,ANXIETY,PSYCHIATRIC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,144,11
Placebo,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,5,N_and_N_pct,7,2
Placebo,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,9,AEs,7,2
Placebo,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.05813953488372093,N_and_N_pct,7,2
Placebo,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,3,N_and_N_pct,2,2
Placebo,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,3,AEs,2,2
Placebo,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.03488372093023256,N_and_N_pct,2,2
Placebo,APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,18,2
Placebo,APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,18,2
Placebo,APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.011627906976744186,N_and_N_pct,18,2
Placebo,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,3,N_and_N_pct,6,2
Placebo,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,7,AEs,6,2
Placebo,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.03488372093023256,N_and_N_pct,6,2
Placebo,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,6,N_and_N_pct,3,2
Placebo,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,10,AEs,3,2
Placebo,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.06976744186046512,N_and_N_pct,3,2
Placebo,APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,21,2
Placebo,APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,21,2
Placebo,APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.011627906976744186,N_and_N_pct,21,2
Placebo,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,5,2
Placebo,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,5,2
Placebo,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.011627906976744186,N_and_N_pct,5,2
Placebo,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,32,8
Placebo,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,1,AEs,32,8
Placebo,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,32,8
Placebo,ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,109,8
Placebo,ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,2,AEs,109,8
Placebo,ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,109,8
Placebo,ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,205,2
Placebo,ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,205,2
Placebo,ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.011627906976744186,N_and_N_pct,205,2
Placebo,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N,1,N_and_N_pct,129,6
Placebo,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N_tot,1,AEs,129,6
Placebo,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,129,6
Placebo,ATRIAL HYPERTROPHY,CARDIAC DISORDERS,N,1,N_and_N_pct,160,6
Placebo,ATRIAL HYPERTROPHY,CARDIAC DISORDERS,N_tot,2,AEs,160,6
Placebo,ATRIAL HYPERTROPHY,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,160,6
Placebo,ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,N,1,N_and_N_pct,191,6
Placebo,ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,N_tot,1,AEs,191,6
Placebo,ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,191,6
Placebo,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N,2,N_and_N_pct,24,6
Placebo,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N_tot,2,AEs,24,6
Placebo,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,24,6
Placebo,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,91,8
Placebo,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,2,AEs,91,8
Placebo,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,91,8
Placebo,BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N,1,N_and_N_pct,100,17
Placebo,BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N_tot,2,AEs,100,17
Placebo,BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,100,17
Placebo,BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,179,14
Placebo,BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,N_tot,1,AEs,179,14
Placebo,BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,N_pct,0.011627906976744186,N_and_N_pct,179,14
Placebo,BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,147,14
Placebo,BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,N_tot,2,AEs,147,14
Placebo,BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,N_pct,0.011627906976744186,N_and_N_pct,147,14
Placebo,BLOOD URINE PRESENT,INVESTIGATIONS,N,1,N_and_N_pct,166,14
Placebo,BLOOD URINE PRESENT,INVESTIGATIONS,N_tot,1,AEs,166,14
Placebo,BLOOD URINE PRESENT,INVESTIGATIONS,N_pct,0.011627906976744186,N_and_N_pct,166,14
Placebo,BRADYCARDIA,CARDIAC DISORDERS,N,1,N_and_N_pct,233,6
Placebo,BRADYCARDIA,CARDIAC DISORDERS,N_tot,4,AEs,233,6
Placebo,BRADYCARDIA,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,233,6
Placebo,BRONCHITIS,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,214,7
Placebo,BRONCHITIS,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,214,7
Placebo,BRONCHITIS,INFECTIONS AND INFESTATIONS,N_pct,0.011627906976744186,N_and_N_pct,214,7
Placebo,BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,N,1,N_and_N_pct,26,6
Placebo,BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,N_tot,1,AEs,26,6
Placebo,BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,26,6
Placebo,BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,N,1,N_and_N_pct,215,6
Placebo,BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,N_tot,2,AEs,215,6
Placebo,BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,215,6
Placebo,CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,N,1,N_and_N_pct,193,6
Placebo,CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,N_tot,1,AEs,193,6
Placebo,CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,193,6
Placebo,CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,N,1,N_and_N_pct,104,15
Placebo,CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,N_tot,1,AEs,104,15
Placebo,CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,N_pct,0.011627906976744186,N_and_N_pct,104,15
Placebo,CERVICITIS,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,208,7
Placebo,CERVICITIS,INFECTIONS AND INFESTATIONS,N_tot,2,AEs,208,7
Placebo,CERVICITIS,INFECTIONS AND INFESTATIONS,N_pct,0.011627906976744186,N_and_N_pct,208,7
Placebo,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,103,2
Placebo,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,3,AEs,103,2
Placebo,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.011627906976744186,N_and_N_pct,103,2
Placebo,COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,192,3
Placebo,COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,3,AEs,192,3
Placebo,COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,192,3
Placebo,COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,137,11
Placebo,COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,N_tot,1,AEs,137,11
Placebo,COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,137,11
Placebo,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N,2,N_and_N_pct,62,11
Placebo,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N_tot,2,AEs,62,11
Placebo,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,62,11
Placebo,CONJUNCTIVITIS,EYE DISORDERS,N,2,N_and_N_pct,148,10
Placebo,CONJUNCTIVITIS,EYE DISORDERS,N_tot,4,AEs,148,10
Placebo,CONJUNCTIVITIS,EYE DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,148,10
Placebo,CONSTIPATION,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,159,5
Placebo,CONSTIPATION,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,159,5
Placebo,CONSTIPATION,GASTROINTESTINAL DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,159,5
Placebo,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,75,16
Placebo,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,1,AEs,75,16
Placebo,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.011627906976744186,N_and_N_pct,75,16
Placebo,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,3,N_and_N_pct,37,4
Placebo,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,4,AEs,37,4
Placebo,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.03488372093023256,N_and_N_pct,37,4
Placebo,CYSTITIS,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,117,7
Placebo,CYSTITIS,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,117,7
Placebo,CYSTITIS,INFECTIONS AND INFESTATIONS,N_pct,0.011627906976744186,N_and_N_pct,117,7
Placebo,CYSTOSCOPY,INVESTIGATIONS,N,1,N_and_N_pct,167,14
Placebo,CYSTOSCOPY,INVESTIGATIONS,N_tot,1,AEs,167,14
Placebo,CYSTOSCOPY,INVESTIGATIONS,N_pct,0.011627906976744186,N_and_N_pct,167,14
Placebo,DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,107,12
Placebo,DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N_tot,2,AEs,107,12
Placebo,DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,107,12
Placebo,DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,168,12
Placebo,DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,N_tot,1,AEs,168,12
Placebo,DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,168,12
Placebo,DELUSION,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,195,11
Placebo,DELUSION,PSYCHIATRIC DISORDERS,N_tot,1,AEs,195,11
Placebo,DELUSION,PSYCHIATRIC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,195,11
Placebo,DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,239,3
Placebo,DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,1,AEs,239,3
Placebo,DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,239,3
Placebo,DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,171,12
Placebo,DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,N_tot,1,AEs,171,12
Placebo,DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,171,12
Placebo,DIARRHOEA,GASTROINTESTINAL DISORDERS,N,9,N_and_N_pct,23,5
Placebo,DIARRHOEA,GASTROINTESTINAL DISORDERS,N_tot,10,AEs,23,5
Placebo,DIARRHOEA,GASTROINTESTINAL DISORDERS,N_pct,0.10465116279069768,N_and_N_pct,23,5
Placebo,DISORIENTATION,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,108,11
Placebo,DISORIENTATION,PSYCHIATRIC DISORDERS,N_tot,1,AEs,108,11
Placebo,DISORIENTATION,PSYCHIATRIC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,108,11
Placebo,DIZZINESS,NERVOUS SYSTEM DISORDERS,N,2,N_and_N_pct,76,13
Placebo,DIZZINESS,NERVOUS SYSTEM DISORDERS,N_tot,3,AEs,76,13
Placebo,DIZZINESS,NERVOUS SYSTEM DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,76,13
Placebo,DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,172,3
Placebo,DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,1,AEs,172,3
Placebo,DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,172,3
Placebo,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,47,5
Placebo,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N_tot,2,AEs,47,5
Placebo,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,47,5
Placebo,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,63,4
Placebo,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,63,4
Placebo,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.011627906976744186,N_and_N_pct,63,4
Placebo,DYSURIA,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,209,9
Placebo,DYSURIA,RENAL AND URINARY DISORDERS,N_tot,1,AEs,209,9
Placebo,DYSURIA,RENAL AND URINARY DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,209,9
Placebo,EAR INFECTION,INFECTIONS AND INFESTATIONS,N,2,N_and_N_pct,199,7
Placebo,EAR INFECTION,INFECTIONS AND INFESTATIONS,N_tot,4,AEs,199,7
Placebo,EAR INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.023255813953488372,N_and_N_pct,199,7
Placebo,EAR PAIN,EAR AND LABYRINTH DISORDERS,N,1,N_and_N_pct,216,20
Placebo,EAR PAIN,EAR AND LABYRINTH DISORDERS,N_tot,2,AEs,216,20
Placebo,EAR PAIN,EAR AND LABYRINTH DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,216,20
Placebo,ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,N,4,N_and_N_pct,122,14
Placebo,ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,N_tot,4,AEs,122,14
Placebo,ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,N_pct,0.046511627906976744,N_and_N_pct,122,14
Placebo,ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,N,1,N_and_N_pct,197,14
Placebo,ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,N_tot,1,AEs,197,14
Placebo,ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,N_pct,0.011627906976744186,N_and_N_pct,197,14
Placebo,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N,2,N_and_N_pct,163,14
Placebo,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N_tot,3,AEs,163,14
Placebo,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N_pct,0.023255813953488372,N_and_N_pct,163,14
Placebo,EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,217,4
Placebo,EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,217,4
Placebo,EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.011627906976744186,N_and_N_pct,217,4
Placebo,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,9,N_and_N_pct,4,3
Placebo,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,13,AEs,4,3
Placebo,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.10465116279069768,N_and_N_pct,4,3
Placebo,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,2,N_and_N_pct,118,16
Placebo,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,3,AEs,118,16
Placebo,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.023255813953488372,N_and_N_pct,118,16
Placebo,EYE ALLERGY,EYE DISORDERS,N,1,N_and_N_pct,38,10
Placebo,EYE ALLERGY,EYE DISORDERS,N_tot,1,AEs,38,10
Placebo,EYE ALLERGY,EYE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,38,10
Placebo,EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,N,1,N_and_N_pct,61,15
Placebo,EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,N_tot,1,AEs,61,15
Placebo,EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,N_pct,0.011627906976744186,N_and_N_pct,61,15
Placebo,EYE PRURITUS,EYE DISORDERS,N,1,N_and_N_pct,39,10
Placebo,EYE PRURITUS,EYE DISORDERS,N_tot,1,AEs,39,10
Placebo,EYE PRURITUS,EYE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,39,10
Placebo,EYE SWELLING,EYE DISORDERS,N,1,N_and_N_pct,40,10
Placebo,EYE SWELLING,EYE DISORDERS,N_tot,1,AEs,40,10
Placebo,EYE SWELLING,EYE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,40,10
Placebo,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,181,16
Placebo,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,2,AEs,181,16
Placebo,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.011627906976744186,N_and_N_pct,181,16
Placebo,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,25,2
Placebo,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,25,2
Placebo,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.011627906976744186,N_and_N_pct,25,2
Placebo,FLATULENCE,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,134,5
Placebo,FLATULENCE,GASTROINTESTINAL DISORDERS,N_tot,2,AEs,134,5
Placebo,FLATULENCE,GASTROINTESTINAL DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,134,5
Placebo,FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,234,12
Placebo,FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,N_tot,1,AEs,234,12
Placebo,FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,234,12
Placebo,GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,210,7
Placebo,GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,210,7
Placebo,GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,N_pct,0.011627906976744186,N_and_N_pct,210,7
Placebo,GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,211,5
Placebo,GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,211,5
Placebo,GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,211,5
Placebo,GLAUCOMA,EYE DISORDERS,N,1,N_and_N_pct,110,10
Placebo,GLAUCOMA,EYE DISORDERS,N_tot,1,AEs,110,10
Placebo,GLAUCOMA,EYE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,110,10
Placebo,GLOSSITIS,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,200,5
Placebo,GLOSSITIS,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,200,5
Placebo,GLOSSITIS,GASTROINTESTINAL DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,200,5
Placebo,HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,184,4
Placebo,HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,2,AEs,184,4
Placebo,HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.011627906976744186,N_and_N_pct,184,4
Placebo,HEADACHE,NERVOUS SYSTEM DISORDERS,N,7,N_and_N_pct,52,13
Placebo,HEADACHE,NERVOUS SYSTEM DISORDERS,N_tot,8,AEs,52,13
Placebo,HEADACHE,NERVOUS SYSTEM DISORDERS,N_pct,0.08139534883720931,N_and_N_pct,52,13
Placebo,HEART RATE INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,155,14
Placebo,HEART RATE INCREASED,INVESTIGATIONS,N_tot,2,AEs,155,14
Placebo,HEART RATE INCREASED,INVESTIGATIONS,N_pct,0.011627906976744186,N_and_N_pct,155,14
Placebo,HEART RATE IRREGULAR,INVESTIGATIONS,N,1,N_and_N_pct,153,14
Placebo,HEART RATE IRREGULAR,INVESTIGATIONS,N_tot,4,AEs,153,14
Placebo,HEART RATE IRREGULAR,INVESTIGATIONS,N_pct,0.011627906976744186,N_and_N_pct,153,14
Placebo,HIATUS HERNIA,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,27,5
Placebo,HIATUS HERNIA,GASTROINTESTINAL DISORDERS,N_tot,2,AEs,27,5
Placebo,HIATUS HERNIA,GASTROINTESTINAL DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,27,5
Placebo,HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,164,16
Placebo,HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,2,AEs,164,16
Placebo,HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.011627906976744186,N_and_N_pct,164,16
Placebo,HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,N,1,N_and_N_pct,138,22
Placebo,HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,N_tot,1,AEs,138,22
Placebo,HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,138,22
Placebo,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,2,N_and_N_pct,78,3
Placebo,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,78,3
Placebo,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,78,3
Placebo,HYPERTENSION,VASCULAR DISORDERS,N,1,N_and_N_pct,206,18
Placebo,HYPERTENSION,VASCULAR DISORDERS,N_tot,2,AEs,206,18
Placebo,HYPERTENSION,VASCULAR DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,206,18
Placebo,HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,194,12
Placebo,HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,N_tot,1,AEs,194,12
Placebo,HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,194,12
Placebo,HYPOTENSION,VASCULAR DISORDERS,N,2,N_and_N_pct,111,18
Placebo,HYPOTENSION,VASCULAR DISORDERS,N_tot,3,AEs,111,18
Placebo,HYPOTENSION,VASCULAR DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,111,18
Placebo,INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,51,12
Placebo,INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N_tot,2,AEs,51,12
Placebo,INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,51,12
Placebo,INFLUENZA,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,120,7
Placebo,INFLUENZA,INFECTIONS AND INFESTATIONS,N_tot,2,AEs,120,7
Placebo,INFLUENZA,INFECTIONS AND INFESTATIONS,N_pct,0.011627906976744186,N_and_N_pct,120,7
Placebo,INSOMNIA,PSYCHIATRIC DISORDERS,N,2,N_and_N_pct,99,11
Placebo,INSOMNIA,PSYCHIATRIC DISORDERS,N_tot,3,AEs,99,11
Placebo,INSOMNIA,PSYCHIATRIC DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,99,11
Placebo,IRRITABILITY,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,145,11
Placebo,IRRITABILITY,PSYCHIATRIC DISORDERS,N_tot,2,AEs,145,11
Placebo,IRRITABILITY,PSYCHIATRIC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,145,11
Placebo,LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,34,7
Placebo,LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,N_tot,2,AEs,34,7
Placebo,LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.011627906976744186,N_and_N_pct,34,7
Placebo,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,35,9
Placebo,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N_tot,1,AEs,35,9
Placebo,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,35,9
Placebo,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N,4,N_and_N_pct,112,6
Placebo,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N_tot,4,AEs,112,6
Placebo,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N_pct,0.046511627906976744,N_and_N_pct,112,6
Placebo,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,3,N_and_N_pct,29,4
Placebo,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,3,AEs,29,4
Placebo,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.03488372093023256,N_and_N_pct,29,4
Placebo,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N,2,N_and_N_pct,53,7
Placebo,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N_tot,4,AEs,53,7
Placebo,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N_pct,0.023255813953488372,N_and_N_pct,53,7
Placebo,NAUSEA,GASTROINTESTINAL DISORDERS,N,3,N_and_N_pct,71,5
Placebo,NAUSEA,GASTROINTESTINAL DISORDERS,N_tot,3,AEs,71,5
Placebo,NAUSEA,GASTROINTESTINAL DISORDERS,N_pct,0.03488372093023256,N_and_N_pct,71,5
Placebo,NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,182,9
Placebo,NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,N_tot,1,AEs,182,9
Placebo,NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,182,9
Placebo,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,105,2
Placebo,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,5,AEs,105,2
Placebo,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.023255813953488372,N_and_N_pct,105,2
Placebo,ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,N,1,N_and_N_pct,169,18
Placebo,ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,N_tot,2,AEs,169,18
Placebo,ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,169,18
Placebo,PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,161,8
Placebo,PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,1,AEs,161,8
Placebo,PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,161,8
Placebo,PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,136,13
Placebo,PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,136,13
Placebo,PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,136,13
Placebo,PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N,1,N_and_N_pct,212,17
Placebo,PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N_tot,2,AEs,212,17
Placebo,PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,212,17
Placebo,POLLAKIURIA,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,135,9
Placebo,POLLAKIURIA,RENAL AND URINARY DISORDERS,N_tot,2,AEs,135,9
Placebo,POLLAKIURIA,RENAL AND URINARY DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,135,9
Placebo,POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,149,4
Placebo,POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,2,AEs,149,4
Placebo,POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.011627906976744186,N_and_N_pct,149,4
Placebo,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,8,N_and_N_pct,36,3
Placebo,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,11,AEs,36,3
Placebo,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.09302325581395349,N_and_N_pct,36,3
Placebo,PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,196,13
Placebo,PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,196,13
Placebo,PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,196,13
Placebo,PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,41,2
Placebo,PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,41,2
Placebo,PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.023255813953488372,N_and_N_pct,41,2
Placebo,RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,185,4
Placebo,RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,2,AEs,185,4
Placebo,RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.011627906976744186,N_and_N_pct,185,4
Placebo,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,5,N_and_N_pct,43,3
Placebo,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,9,AEs,43,3
Placebo,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.05813953488372093,N_and_N_pct,43,3
Placebo,SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,66,8
Placebo,SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,2,AEs,66,8
Placebo,SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,66,8
Placebo,SINUS ARRHYTHMIA,CARDIAC DISORDERS,N,1,N_and_N_pct,150,6
Placebo,SINUS ARRHYTHMIA,CARDIAC DISORDERS,N_tot,2,AEs,150,6
Placebo,SINUS ARRHYTHMIA,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,150,6
Placebo,SINUS BRADYCARDIA,CARDIAC DISORDERS,N,2,N_and_N_pct,115,6
Placebo,SINUS BRADYCARDIA,CARDIAC DISORDERS,N_tot,2,AEs,115,6
Placebo,SINUS BRADYCARDIA,CARDIAC DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,115,6
Placebo,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,3,N_and_N_pct,96,3
Placebo,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,4,AEs,96,3
Placebo,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.03488372093023256,N_and_N_pct,96,3
Placebo,SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,67,16
Placebo,SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,1,AEs,67,16
Placebo,SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.011627906976744186,N_and_N_pct,67,16
Placebo,SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,240,3
Placebo,SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,240,3
Placebo,SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,240,3
Placebo,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N,2,N_and_N_pct,106,13
Placebo,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N_tot,3,AEs,106,13
Placebo,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N_pct,0.023255813953488372,N_and_N_pct,106,13
Placebo,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N,1,N_and_N_pct,188,6
Placebo,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_tot,2,AEs,188,6
Placebo,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,188,6
Placebo,TACHYCARDIA,CARDIAC DISORDERS,N,1,N_and_N_pct,113,6
Placebo,TACHYCARDIA,CARDIAC DISORDERS,N_tot,2,AEs,113,6
Placebo,TACHYCARDIA,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,113,6
Placebo,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N,6,N_and_N_pct,28,7
Placebo,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_tot,12,AEs,28,7
Placebo,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.06976744186046512,N_and_N_pct,28,7
Placebo,URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N,2,N_and_N_pct,42,7
Placebo,URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_tot,4,AEs,42,7
Placebo,URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.023255813953488372,N_and_N_pct,42,7
Placebo,VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,213,7
Placebo,VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,N_tot,2,AEs,213,7
Placebo,VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,N_pct,0.011627906976744186,N_and_N_pct,213,7
Placebo,VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,N,1,N_and_N_pct,141,6
Placebo,VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,N_tot,1,AEs,141,6
Placebo,VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,N_pct,0.011627906976744186,N_and_N_pct,141,6
Placebo,VOMITING,GASTROINTESTINAL DISORDERS,N,3,N_and_N_pct,54,5
Placebo,VOMITING,GASTROINTESTINAL DISORDERS,N_tot,3,AEs,54,5
Placebo,VOMITING,GASTROINTESTINAL DISORDERS,N_pct,0.03488372093023256,N_and_N_pct,54,5
Xanomeline High Dose,ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,126,5
Xanomeline High Dose,ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,126,5
Xanomeline High Dose,ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,126,5
Xanomeline High Dose,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,142,5
Xanomeline High Dose,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N_tot,2,AEs,142,5
Xanomeline High Dose,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,142,5
Xanomeline High Dose,ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,N,1,N_and_N_pct,162,15
Xanomeline High Dose,ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,N_tot,1,AEs,162,15
Xanomeline High Dose,ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,N_pct,0.013888888888888888,N_and_N_pct,162,15
Xanomeline High Dose,ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,44,3
Xanomeline High Dose,ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,1,AEs,44,3
Xanomeline High Dose,ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,44,3
Xanomeline High Dose,ALCOHOL USE,SOCIAL CIRCUMSTANCES,N,1,N_and_N_pct,154,24
Xanomeline High Dose,ALCOHOL USE,SOCIAL CIRCUMSTANCES,N_tot,1,AEs,154,24
Xanomeline High Dose,ALCOHOL USE,SOCIAL CIRCUMSTANCES,N_pct,0.013888888888888888,N_and_N_pct,154,24
Xanomeline High Dose,ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,173,4
Xanomeline High Dose,ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,173,4
Xanomeline High Dose,ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.013888888888888888,N_and_N_pct,173,4
Xanomeline High Dose,AMNESIA,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,243,13
Xanomeline High Dose,AMNESIA,NERVOUS SYSTEM DISORDERS,N_tot,2,AEs,243,13
Xanomeline High Dose,AMNESIA,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,243,13
Xanomeline High Dose,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,7,N_and_N_pct,7,2
Xanomeline High Dose,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,12,AEs,7,2
Xanomeline High Dose,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.09722222222222222,N_and_N_pct,7,2
Xanomeline High Dose,APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,16,2
Xanomeline High Dose,APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,16,2
Xanomeline High Dose,APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.013888888888888888,N_and_N_pct,16,2
Xanomeline High Dose,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,14,N_and_N_pct,2,2
Xanomeline High Dose,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,22,AEs,2,2
Xanomeline High Dose,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.19444444444444445,N_and_N_pct,2,2
Xanomeline High Dose,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,9,N_and_N_pct,6,2
Xanomeline High Dose,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,16,AEs,6,2
Xanomeline High Dose,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.125,N_and_N_pct,6,2
Xanomeline High Dose,APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,8,2
Xanomeline High Dose,APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,8,2
Xanomeline High Dose,APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.027777777777777776,N_and_N_pct,8,2
Xanomeline High Dose,APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,11,2
Xanomeline High Dose,APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,3,AEs,11,2
Xanomeline High Dose,APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.027777777777777776,N_and_N_pct,11,2
Xanomeline High Dose,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,21,N_and_N_pct,3,2
Xanomeline High Dose,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,34,AEs,3,2
Xanomeline High Dose,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.2916666666666667,N_and_N_pct,3,2
Xanomeline High Dose,APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,21,2
Xanomeline High Dose,APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,21,2
Xanomeline High Dose,APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.013888888888888888,N_and_N_pct,21,2
Xanomeline High Dose,APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,13,2
Xanomeline High Dose,APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,3,AEs,13,2
Xanomeline High Dose,APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.027777777777777776,N_and_N_pct,13,2
Xanomeline High Dose,APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,9,2
Xanomeline High Dose,APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,9,2
Xanomeline High Dose,APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.013888888888888888,N_and_N_pct,9,2
Xanomeline High Dose,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,5,N_and_N_pct,5,2
Xanomeline High Dose,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,5,AEs,5,2
Xanomeline High Dose,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.06944444444444445,N_and_N_pct,5,2
Xanomeline High Dose,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,32,8
Xanomeline High Dose,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,1,AEs,32,8
Xanomeline High Dose,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,32,8
Xanomeline High Dose,ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,109,8
Xanomeline High Dose,ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,1,AEs,109,8
Xanomeline High Dose,ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,109,8
Xanomeline High Dose,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N,2,N_and_N_pct,129,6
Xanomeline High Dose,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N_tot,3,AEs,129,6
Xanomeline High Dose,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N_pct,0.027777777777777776,N_and_N_pct,129,6
Xanomeline High Dose,ATRIAL FLUTTER,CARDIAC DISORDERS,N,1,N_and_N_pct,130,6
Xanomeline High Dose,ATRIAL FLUTTER,CARDIAC DISORDERS,N_tot,2,AEs,130,6
Xanomeline High Dose,ATRIAL FLUTTER,CARDIAC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,130,6
Xanomeline High Dose,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N,1,N_and_N_pct,24,6
Xanomeline High Dose,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N_tot,2,AEs,24,6
Xanomeline High Dose,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,24,6
Xanomeline High Dose,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,3,N_and_N_pct,91,8
Xanomeline High Dose,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,4,AEs,91,8
Xanomeline High Dose,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.041666666666666664,N_and_N_pct,91,8
Xanomeline High Dose,BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N,1,N_and_N_pct,100,17
Xanomeline High Dose,BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N_tot,1,AEs,100,17
Xanomeline High Dose,BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,100,17
Xanomeline High Dose,BIOPSY,INVESTIGATIONS,N,1,N_and_N_pct,174,14
Xanomeline High Dose,BIOPSY,INVESTIGATIONS,N_tot,1,AEs,174,14
Xanomeline High Dose,BIOPSY,INVESTIGATIONS,N_pct,0.013888888888888888,N_and_N_pct,174,14
Xanomeline High Dose,BIOPSY PROSTATE,INVESTIGATIONS,N,1,N_and_N_pct,101,14
Xanomeline High Dose,BIOPSY PROSTATE,INVESTIGATIONS,N_tot,1,AEs,101,14
Xanomeline High Dose,BIOPSY PROSTATE,INVESTIGATIONS,N_pct,0.013888888888888888,N_and_N_pct,101,14
Xanomeline High Dose,BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,12,3
Xanomeline High Dose,BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,12,3
Xanomeline High Dose,BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,12,3
Xanomeline High Dose,BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,226,14
Xanomeline High Dose,BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,N_tot,1,AEs,226,14
Xanomeline High Dose,BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,N_pct,0.013888888888888888,N_and_N_pct,226,14
Xanomeline High Dose,BLOOD GLUCOSE INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,127,14
Xanomeline High Dose,BLOOD GLUCOSE INCREASED,INVESTIGATIONS,N_tot,2,AEs,127,14
Xanomeline High Dose,BLOOD GLUCOSE INCREASED,INVESTIGATIONS,N_pct,0.013888888888888888,N_and_N_pct,127,14
Xanomeline High Dose,BURNING SENSATION,NERVOUS SYSTEM DISORDERS,N,2,N_and_N_pct,133,13
Xanomeline High Dose,BURNING SENSATION,NERVOUS SYSTEM DISORDERS,N_tot,2,AEs,133,13
Xanomeline High Dose,BURNING SENSATION,NERVOUS SYSTEM DISORDERS,N_pct,0.027777777777777776,N_and_N_pct,133,13
Xanomeline High Dose,CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,45,9
Xanomeline High Dose,CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,N_tot,1,AEs,45,9
Xanomeline High Dose,CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,45,9
Xanomeline High Dose,CARDIAC DISORDER,CARDIAC DISORDERS,N,1,N_and_N_pct,119,6
Xanomeline High Dose,CARDIAC DISORDER,CARDIAC DISORDERS,N_tot,1,AEs,119,6
Xanomeline High Dose,CARDIAC DISORDER,CARDIAC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,119,6
Xanomeline High Dose,CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,92,2
Xanomeline High Dose,CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,92,2
Xanomeline High Dose,CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.013888888888888888,N_and_N_pct,92,2
Xanomeline High Dose,CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,183,2
Xanomeline High Dose,CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,183,2
Xanomeline High Dose,CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.027777777777777776,N_and_N_pct,183,2
Xanomeline High Dose,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,103,2
Xanomeline High Dose,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,103,2
Xanomeline High Dose,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.013888888888888888,N_and_N_pct,103,2
Xanomeline High Dose,COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,228,13
Xanomeline High Dose,COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,228,13
Xanomeline High Dose,COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,228,13
Xanomeline High Dose,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,62,11
Xanomeline High Dose,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N_tot,1,AEs,62,11
Xanomeline High Dose,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,62,11
Xanomeline High Dose,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,2,N_and_N_pct,75,16
Xanomeline High Dose,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,3,AEs,75,16
Xanomeline High Dose,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.027777777777777776,N_and_N_pct,75,16
Xanomeline High Dose,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,5,N_and_N_pct,37,4
Xanomeline High Dose,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,7,AEs,37,4
Xanomeline High Dose,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.06944444444444445,N_and_N_pct,37,4
Xanomeline High Dose,CYSTITIS,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,117,7
Xanomeline High Dose,CYSTITIS,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,117,7
Xanomeline High Dose,CYSTITIS,INFECTIONS AND INFESTATIONS,N_pct,0.013888888888888888,N_and_N_pct,117,7
Xanomeline High Dose,DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,107,12
Xanomeline High Dose,DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N_tot,2,AEs,107,12
Xanomeline High Dose,DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,107,12
Xanomeline High Dose,DELIRIUM,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,207,11
Xanomeline High Dose,DELIRIUM,PSYCHIATRIC DISORDERS,N_tot,1,AEs,207,11
Xanomeline High Dose,DELIRIUM,PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,207,11
Xanomeline High Dose,DELUSION,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,195,11
Xanomeline High Dose,DELUSION,PSYCHIATRIC DISORDERS,N_tot,1,AEs,195,11
Xanomeline High Dose,DELUSION,PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,195,11
Xanomeline High Dose,DEPRESSED MOOD,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,46,11
Xanomeline High Dose,DEPRESSED MOOD,PSYCHIATRIC DISORDERS,N_tot,1,AEs,46,11
Xanomeline High Dose,DEPRESSED MOOD,PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,46,11
Xanomeline High Dose,DIARRHOEA,GASTROINTESTINAL DISORDERS,N,3,N_and_N_pct,23,5
Xanomeline High Dose,DIARRHOEA,GASTROINTESTINAL DISORDERS,N_tot,3,AEs,23,5
Xanomeline High Dose,DIARRHOEA,GASTROINTESTINAL DISORDERS,N_pct,0.041666666666666664,N_and_N_pct,23,5
Xanomeline High Dose,DIZZINESS,NERVOUS SYSTEM DISORDERS,N,11,N_and_N_pct,76,13
Xanomeline High Dose,DIZZINESS,NERVOUS SYSTEM DISORDERS,N_tot,17,AEs,76,13
Xanomeline High Dose,DIZZINESS,NERVOUS SYSTEM DISORDERS,N_pct,0.1527777777777778,N_and_N_pct,76,13
Xanomeline High Dose,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,47,5
Xanomeline High Dose,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,47,5
Xanomeline High Dose,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,47,5
Xanomeline High Dose,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,63,4
Xanomeline High Dose,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,63,4
Xanomeline High Dose,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.013888888888888888,N_and_N_pct,63,4
Xanomeline High Dose,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N,1,N_and_N_pct,163,14
Xanomeline High Dose,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N_tot,1,AEs,163,14
Xanomeline High Dose,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N_pct,0.013888888888888888,N_and_N_pct,163,14
Xanomeline High Dose,EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,2,N_and_N_pct,48,4
Xanomeline High Dose,EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,2,AEs,48,4
Xanomeline High Dose,EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.027777777777777776,N_and_N_pct,48,4
Xanomeline High Dose,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,14,N_and_N_pct,4,3
Xanomeline High Dose,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,22,AEs,4,3
Xanomeline High Dose,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.19444444444444445,N_and_N_pct,4,3
Xanomeline High Dose,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,118,16
Xanomeline High Dose,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,1,AEs,118,16
Xanomeline High Dose,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.013888888888888888,N_and_N_pct,118,16
Xanomeline High Dose,FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,180,16
Xanomeline High Dose,FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,1,AEs,180,16
Xanomeline High Dose,FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.013888888888888888,N_and_N_pct,180,16
Xanomeline High Dose,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,181,16
Xanomeline High Dose,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,1,AEs,181,16
Xanomeline High Dose,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.013888888888888888,N_and_N_pct,181,16
Xanomeline High Dose,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,5,N_and_N_pct,25,2
Xanomeline High Dose,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,5,AEs,25,2
Xanomeline High Dose,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.06944444444444445,N_and_N_pct,25,2
Xanomeline High Dose,FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,77,2
Xanomeline High Dose,FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,77,2
Xanomeline High Dose,FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.013888888888888888,N_and_N_pct,77,2
Xanomeline High Dose,FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,175,2
Xanomeline High Dose,FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,175,2
Xanomeline High Dose,FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.013888888888888888,N_and_N_pct,175,2
Xanomeline High Dose,FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,2,N_and_N_pct,49,8
Xanomeline High Dose,FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,2,AEs,49,8
Xanomeline High Dose,FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.027777777777777776,N_and_N_pct,49,8
Xanomeline High Dose,GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,187,5
Xanomeline High Dose,GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,187,5
Xanomeline High Dose,GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,187,5
Xanomeline High Dose,HALLUCINATION,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,224,11
Xanomeline High Dose,HALLUCINATION,PSYCHIATRIC DISORDERS,N_tot,1,AEs,224,11
Xanomeline High Dose,HALLUCINATION,PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,224,11
Xanomeline High Dose,"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,241,11
Xanomeline High Dose,"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,N_tot,1,AEs,241,11
Xanomeline High Dose,"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,241,11
Xanomeline High Dose,HEADACHE,NERVOUS SYSTEM DISORDERS,N,6,N_and_N_pct,52,13
Xanomeline High Dose,HEADACHE,NERVOUS SYSTEM DISORDERS,N_tot,9,AEs,52,13
Xanomeline High Dose,HEADACHE,NERVOUS SYSTEM DISORDERS,N_pct,0.08333333333333333,N_and_N_pct,52,13
Xanomeline High Dose,HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,2,N_and_N_pct,164,16
Xanomeline High Dose,HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,2,AEs,164,16
Xanomeline High Dose,HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.027777777777777776,N_and_N_pct,164,16
Xanomeline High Dose,HORDEOLUM,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,69,7
Xanomeline High Dose,HORDEOLUM,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,69,7
Xanomeline High Dose,HORDEOLUM,INFECTIONS AND INFESTATIONS,N_pct,0.013888888888888888,N_and_N_pct,69,7
Xanomeline High Dose,HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,102,12
Xanomeline High Dose,HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,N_tot,1,AEs,102,12
Xanomeline High Dose,HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,102,12
Xanomeline High Dose,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,8,N_and_N_pct,78,3
Xanomeline High Dose,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,10,AEs,78,3
Xanomeline High Dose,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.1111111111111111,N_and_N_pct,78,3
Xanomeline High Dose,HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,220,13
Xanomeline High Dose,HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,220,13
Xanomeline High Dose,HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,220,13
Xanomeline High Dose,INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,51,12
Xanomeline High Dose,INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N_tot,2,AEs,51,12
Xanomeline High Dose,INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,51,12
Xanomeline High Dose,INFLUENZA,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,120,7
Xanomeline High Dose,INFLUENZA,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,120,7
Xanomeline High Dose,INFLUENZA,INFECTIONS AND INFESTATIONS,N_pct,0.013888888888888888,N_and_N_pct,120,7
Xanomeline High Dose,INSOMNIA,PSYCHIATRIC DISORDERS,N,2,N_and_N_pct,99,11
Xanomeline High Dose,INSOMNIA,PSYCHIATRIC DISORDERS,N_tot,2,AEs,99,11
Xanomeline High Dose,INSOMNIA,PSYCHIATRIC DISORDERS,N_pct,0.027777777777777776,N_and_N_pct,99,11
Xanomeline High Dose,LETHARGY,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,218,13
Xanomeline High Dose,LETHARGY,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,218,13
Xanomeline High Dose,LETHARGY,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,218,13
Xanomeline High Dose,LIBIDO DECREASED,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,79,11
Xanomeline High Dose,LIBIDO DECREASED,PSYCHIATRIC DISORDERS,N_tot,1,AEs,79,11
Xanomeline High Dose,LIBIDO DECREASED,PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,79,11
Xanomeline High Dose,LISTLESS,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,80,11
Xanomeline High Dose,LISTLESS,PSYCHIATRIC DISORDERS,N_tot,1,AEs,80,11
Xanomeline High Dose,LISTLESS,PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,80,11
Xanomeline High Dose,LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,50,7
Xanomeline High Dose,LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_tot,2,AEs,50,7
Xanomeline High Dose,LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.013888888888888888,N_and_N_pct,50,7
Xanomeline High Dose,MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,81,2
Xanomeline High Dose,MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,3,AEs,81,2
Xanomeline High Dose,MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.027777777777777776,N_and_N_pct,81,2
Xanomeline High Dose,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,35,9
Xanomeline High Dose,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N_tot,2,AEs,35,9
Xanomeline High Dose,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,35,9
Xanomeline High Dose,MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,157,8
Xanomeline High Dose,MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,2,AEs,157,8
Xanomeline High Dose,MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,157,8
Xanomeline High Dose,MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,82,8
Xanomeline High Dose,MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,1,AEs,82,8
Xanomeline High Dose,MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,82,8
Xanomeline High Dose,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N,4,N_and_N_pct,112,6
Xanomeline High Dose,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N_tot,8,AEs,112,6
Xanomeline High Dose,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N_pct,0.05555555555555555,N_and_N_pct,112,6
Xanomeline High Dose,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,3,N_and_N_pct,29,4
Xanomeline High Dose,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,4,AEs,29,4
Xanomeline High Dose,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.041666666666666664,N_and_N_pct,29,4
Xanomeline High Dose,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N,6,N_and_N_pct,53,7
Xanomeline High Dose,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N_tot,8,AEs,53,7
Xanomeline High Dose,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N_pct,0.08333333333333333,N_and_N_pct,53,7
Xanomeline High Dose,NAUSEA,GASTROINTESTINAL DISORDERS,N,6,N_and_N_pct,71,5
Xanomeline High Dose,NAUSEA,GASTROINTESTINAL DISORDERS,N_tot,13,AEs,71,5
Xanomeline High Dose,NAUSEA,GASTROINTESTINAL DISORDERS,N_pct,0.08333333333333333,N_and_N_pct,71,5
Xanomeline High Dose,NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,182,9
Xanomeline High Dose,NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,N_tot,1,AEs,182,9
Xanomeline High Dose,NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,182,9
Xanomeline High Dose,NIGHTMARE,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,176,11
Xanomeline High Dose,NIGHTMARE,PSYCHIATRIC DISORDERS,N_tot,1,AEs,176,11
Xanomeline High Dose,NIGHTMARE,PSYCHIATRIC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,176,11
Xanomeline High Dose,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,105,2
Xanomeline High Dose,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,3,AEs,105,2
Xanomeline High Dose,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.027777777777777776,N_and_N_pct,105,2
Xanomeline High Dose,PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,83,2
Xanomeline High Dose,PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,83,2
Xanomeline High Dose,PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.013888888888888888,N_and_N_pct,83,2
Xanomeline High Dose,PARAESTHESIA,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,93,13
Xanomeline High Dose,PARAESTHESIA,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,93,13
Xanomeline High Dose,PARAESTHESIA,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,93,13
Xanomeline High Dose,PAROSMIA,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,72,13
Xanomeline High Dose,PAROSMIA,NERVOUS SYSTEM DISORDERS,N_tot,2,AEs,72,13
Xanomeline High Dose,PAROSMIA,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,72,13
Xanomeline High Dose,PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,242,13
Xanomeline High Dose,PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,242,13
Xanomeline High Dose,PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,242,13
Xanomeline High Dose,PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,15,4
Xanomeline High Dose,PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,2,AEs,15,4
Xanomeline High Dose,PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.013888888888888888,N_and_N_pct,15,4
Xanomeline High Dose,PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,30,4
Xanomeline High Dose,PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,30,4
Xanomeline High Dose,PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.013888888888888888,N_and_N_pct,30,4
Xanomeline High Dose,PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,84,4
Xanomeline High Dose,PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,84,4
Xanomeline High Dose,PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.013888888888888888,N_and_N_pct,84,4
Xanomeline High Dose,PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N,1,N_and_N_pct,225,23
Xanomeline High Dose,PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N_tot,1,AEs,225,23
Xanomeline High Dose,PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N_pct,0.013888888888888888,N_and_N_pct,225,23
Xanomeline High Dose,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,26,N_and_N_pct,36,3
Xanomeline High Dose,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,38,AEs,36,3
Xanomeline High Dose,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.3611111111111111,N_and_N_pct,36,3
Xanomeline High Dose,PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,31,3
Xanomeline High Dose,PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,1,AEs,31,3
Xanomeline High Dose,PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,31,3
Xanomeline High Dose,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,11,N_and_N_pct,43,3
Xanomeline High Dose,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,18,AEs,43,3
Xanomeline High Dose,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.1527777777777778,N_and_N_pct,43,3
Xanomeline High Dose,RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,177,3
Xanomeline High Dose,RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,3,AEs,177,3
Xanomeline High Dose,RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,177,3
Xanomeline High Dose,RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,178,3
Xanomeline High Dose,RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,178,3
Xanomeline High Dose,RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,178,3
Xanomeline High Dose,RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,2,N_and_N_pct,139,3
Xanomeline High Dose,RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,3,AEs,139,3
Xanomeline High Dose,RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.027777777777777776,N_and_N_pct,139,3
Xanomeline High Dose,RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,85,4
Xanomeline High Dose,RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,85,4
Xanomeline High Dose,RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.013888888888888888,N_and_N_pct,85,4
Xanomeline High Dose,RHINITIS,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,86,7
Xanomeline High Dose,RHINITIS,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,86,7
Xanomeline High Dose,RHINITIS,INFECTIONS AND INFESTATIONS,N_pct,0.013888888888888888,N_and_N_pct,86,7
Xanomeline High Dose,RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,74,4
Xanomeline High Dose,RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,2,AEs,74,4
Xanomeline High Dose,RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.013888888888888888,N_and_N_pct,74,4
Xanomeline High Dose,SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,N,4,N_and_N_pct,73,5
Xanomeline High Dose,SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,N_tot,5,AEs,73,5
Xanomeline High Dose,SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,N_pct,0.05555555555555555,N_and_N_pct,73,5
Xanomeline High Dose,SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,N,1,N_and_N_pct,131,21
Xanomeline High Dose,SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,N_tot,1,AEs,131,21
Xanomeline High Dose,SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,131,21
Xanomeline High Dose,SINUS BRADYCARDIA,CARDIAC DISORDERS,N,8,N_and_N_pct,115,6
Xanomeline High Dose,SINUS BRADYCARDIA,CARDIAC DISORDERS,N_tot,12,AEs,115,6
Xanomeline High Dose,SINUS BRADYCARDIA,CARDIAC DISORDERS,N_pct,0.1111111111111111,N_and_N_pct,115,6
Xanomeline High Dose,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,5,N_and_N_pct,96,3
Xanomeline High Dose,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,8,AEs,96,3
Xanomeline High Dose,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.06944444444444445,N_and_N_pct,96,3
Xanomeline High Dose,SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,N,1,N_and_N_pct,165,15
Xanomeline High Dose,SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,N_tot,1,AEs,165,15
Xanomeline High Dose,SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,N_pct,0.013888888888888888,N_and_N_pct,165,15
Xanomeline High Dose,SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,70,3
Xanomeline High Dose,SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,1,AEs,70,3
Xanomeline High Dose,SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,70,3
Xanomeline High Dose,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,106,13
Xanomeline High Dose,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,106,13
Xanomeline High Dose,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,106,13
Xanomeline High Dose,STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,87,5
Xanomeline High Dose,STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,87,5
Xanomeline High Dose,STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,87,5
Xanomeline High Dose,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N,1,N_and_N_pct,188,6
Xanomeline High Dose,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_tot,1,AEs,188,6
Xanomeline High Dose,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,188,6
Xanomeline High Dose,SYNCOPE,NERVOUS SYSTEM DISORDERS,N,2,N_and_N_pct,146,13
Xanomeline High Dose,SYNCOPE,NERVOUS SYSTEM DISORDERS,N_tot,3,AEs,146,13
Xanomeline High Dose,SYNCOPE,NERVOUS SYSTEM DISORDERS,N_pct,0.027777777777777776,N_and_N_pct,146,13
Xanomeline High Dose,SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,189,13
Xanomeline High Dose,SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,189,13
Xanomeline High Dose,SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,189,13
Xanomeline High Dose,TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,116,13
Xanomeline High Dose,TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,116,13
Xanomeline High Dose,TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,116,13
Xanomeline High Dose,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N,3,N_and_N_pct,28,7
Xanomeline High Dose,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_tot,5,AEs,28,7
Xanomeline High Dose,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.041666666666666664,N_and_N_pct,28,7
Xanomeline High Dose,URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,42,7
Xanomeline High Dose,URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,42,7
Xanomeline High Dose,URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.013888888888888888,N_and_N_pct,42,7
Xanomeline High Dose,URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,56,3
Xanomeline High Dose,URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,56,3
Xanomeline High Dose,URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,56,3
Xanomeline High Dose,VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N,1,N_and_N_pct,158,6
Xanomeline High Dose,VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_tot,1,AEs,158,6
Xanomeline High Dose,VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,158,6
Xanomeline High Dose,VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",N,2,N_and_N_pct,121,19
Xanomeline High Dose,VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",N_tot,2,AEs,121,19
Xanomeline High Dose,VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",N_pct,0.027777777777777776,N_and_N_pct,121,19
Xanomeline High Dose,VERTIGO,EAR AND LABYRINTH DISORDERS,N,1,N_and_N_pct,124,20
Xanomeline High Dose,VERTIGO,EAR AND LABYRINTH DISORDERS,N_tot,1,AEs,124,20
Xanomeline High Dose,VERTIGO,EAR AND LABYRINTH DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,124,20
Xanomeline High Dose,VISION BLURRED,EYE DISORDERS,N,1,N_and_N_pct,152,10
Xanomeline High Dose,VISION BLURRED,EYE DISORDERS,N_tot,2,AEs,152,10
Xanomeline High Dose,VISION BLURRED,EYE DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,152,10
Xanomeline High Dose,VOMITING,GASTROINTESTINAL DISORDERS,N,6,N_and_N_pct,54,5
Xanomeline High Dose,VOMITING,GASTROINTESTINAL DISORDERS,N_tot,8,AEs,54,5
Xanomeline High Dose,VOMITING,GASTROINTESTINAL DISORDERS,N_pct,0.08333333333333333,N_and_N_pct,54,5
Xanomeline High Dose,WOUND HAEMORRHAGE,VASCULAR DISORDERS,N,1,N_and_N_pct,140,18
Xanomeline High Dose,WOUND HAEMORRHAGE,VASCULAR DISORDERS,N_tot,1,AEs,140,18
Xanomeline High Dose,WOUND HAEMORRHAGE,VASCULAR DISORDERS,N_pct,0.013888888888888888,N_and_N_pct,140,18
Xanomeline Low Dose,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N,3,N_and_N_pct,142,5
Xanomeline Low Dose,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N_tot,3,AEs,142,5
Xanomeline Low Dose,ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,N_pct,0.03125,N_and_N_pct,142,5
Xanomeline Low Dose,AGITATION,PSYCHIATRIC DISORDERS,N,3,N_and_N_pct,55,11
Xanomeline Low Dose,AGITATION,PSYCHIATRIC DISORDERS,N_tot,3,AEs,55,11
Xanomeline Low Dose,AGITATION,PSYCHIATRIC DISORDERS,N_pct,0.03125,N_and_N_pct,55,11
Xanomeline Low Dose,ANXIETY,PSYCHIATRIC DISORDERS,N,3,N_and_N_pct,144,11
Xanomeline Low Dose,ANXIETY,PSYCHIATRIC DISORDERS,N_tot,4,AEs,144,11
Xanomeline Low Dose,ANXIETY,PSYCHIATRIC DISORDERS,N_pct,0.03125,N_and_N_pct,144,11
Xanomeline Low Dose,APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,17,2
Xanomeline Low Dose,APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,17,2
Xanomeline Low Dose,APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,17,2
Xanomeline Low Dose,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,9,N_and_N_pct,7,2
Xanomeline Low Dose,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,15,AEs,7,2
Xanomeline Low Dose,APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.09375,N_and_N_pct,7,2
Xanomeline Low Dose,APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,19,2
Xanomeline Low Dose,APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,19,2
Xanomeline Low Dose,APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,19,2
Xanomeline Low Dose,APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,22,2
Xanomeline Low Dose,APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,22,2
Xanomeline Low Dose,APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,22,2
Xanomeline Low Dose,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,13,N_and_N_pct,2,2
Xanomeline Low Dose,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,21,AEs,2,2
Xanomeline Low Dose,APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.13541666666666666,N_and_N_pct,2,2
Xanomeline Low Dose,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,9,N_and_N_pct,6,2
Xanomeline Low Dose,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,18,AEs,6,2
Xanomeline Low Dose,APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.09375,N_and_N_pct,6,2
Xanomeline Low Dose,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,23,N_and_N_pct,3,2
Xanomeline Low Dose,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,34,AEs,3,2
Xanomeline Low Dose,APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.23958333333333334,N_and_N_pct,3,2
Xanomeline Low Dose,APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,13,2
Xanomeline Low Dose,APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,13,2
Xanomeline Low Dose,APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,13,2
Xanomeline Low Dose,APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,9,2
Xanomeline Low Dose,APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,9,2
Xanomeline Low Dose,APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.020833333333333332,N_and_N_pct,9,2
Xanomeline Low Dose,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,5,N_and_N_pct,5,2
Xanomeline Low Dose,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,6,AEs,5,2
Xanomeline Low Dose,APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.052083333333333336,N_and_N_pct,5,2
Xanomeline Low Dose,APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,14,2
Xanomeline Low Dose,APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,14,2
Xanomeline Low Dose,APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,14,2
Xanomeline Low Dose,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,2,N_and_N_pct,32,8
Xanomeline Low Dose,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,4,AEs,32,8
Xanomeline Low Dose,ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,32,8
Xanomeline Low Dose,ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,205,2
Xanomeline Low Dose,ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,205,2
Xanomeline Low Dose,ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,205,2
Xanomeline Low Dose,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N,2,N_and_N_pct,129,6
Xanomeline Low Dose,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N_tot,3,AEs,129,6
Xanomeline Low Dose,ATRIAL FIBRILLATION,CARDIAC DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,129,6
Xanomeline Low Dose,ATRIAL FLUTTER,CARDIAC DISORDERS,N,1,N_and_N_pct,130,6
Xanomeline Low Dose,ATRIAL FLUTTER,CARDIAC DISORDERS,N_tot,1,AEs,130,6
Xanomeline Low Dose,ATRIAL FLUTTER,CARDIAC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,130,6
Xanomeline Low Dose,ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,N,1,N_and_N_pct,191,6
Xanomeline Low Dose,ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,N_tot,1,AEs,191,6
Xanomeline Low Dose,ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,191,6
Xanomeline Low Dose,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N,2,N_and_N_pct,24,6
Xanomeline Low Dose,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N_tot,2,AEs,24,6
Xanomeline Low Dose,ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,24,6
Xanomeline Low Dose,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,91,8
Xanomeline Low Dose,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,1,AEs,91,8
Xanomeline Low Dose,BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,91,8
Xanomeline Low Dose,BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,236,13
Xanomeline Low Dose,BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,N_tot,3,AEs,236,13
Xanomeline Low Dose,BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,236,13
Xanomeline Low Dose,BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,5,N_and_N_pct,12,3
Xanomeline Low Dose,BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,8,AEs,12,3
Xanomeline Low Dose,BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.052083333333333336,N_and_N_pct,12,3
Xanomeline Low Dose,BLOOD GLUCOSE INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,127,14
Xanomeline Low Dose,BLOOD GLUCOSE INCREASED,INVESTIGATIONS,N_tot,1,AEs,127,14
Xanomeline Low Dose,BLOOD GLUCOSE INCREASED,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,127,14
Xanomeline Low Dose,BODY TEMPERATURE INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,235,14
Xanomeline Low Dose,BODY TEMPERATURE INCREASED,INVESTIGATIONS,N_tot,1,AEs,235,14
Xanomeline Low Dose,BODY TEMPERATURE INCREASED,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,235,14
Xanomeline Low Dose,BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,N,1,N_and_N_pct,215,6
Xanomeline Low Dose,BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,N_tot,1,AEs,215,6
Xanomeline Low Dose,BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,215,6
Xanomeline Low Dose,CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,N,1,N_and_N_pct,104,15
Xanomeline Low Dose,CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,N_tot,1,AEs,104,15
Xanomeline Low Dose,CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,N_pct,0.010416666666666666,N_and_N_pct,104,15
Xanomeline Low Dose,CELLULITIS,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,33,7
Xanomeline Low Dose,CELLULITIS,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,33,7
Xanomeline Low Dose,CELLULITIS,INFECTIONS AND INFESTATIONS,N_pct,0.010416666666666666,N_and_N_pct,33,7
Xanomeline Low Dose,CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,N,1,N_and_N_pct,201,20
Xanomeline Low Dose,CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,N_tot,1,AEs,201,20
Xanomeline Low Dose,CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,201,20
Xanomeline Low Dose,CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,92,2
Xanomeline Low Dose,CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,92,2
Xanomeline Low Dose,CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,92,2
Xanomeline Low Dose,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,103,2
Xanomeline Low Dose,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,103,2
Xanomeline Low Dose,CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,103,2
Xanomeline Low Dose,COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N,1,N_and_N_pct,143,23
Xanomeline Low Dose,COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N_tot,1,AEs,143,23
Xanomeline Low Dose,COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N_pct,0.010416666666666666,N_and_N_pct,143,23
Xanomeline Low Dose,COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,190,13
Xanomeline Low Dose,COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,190,13
Xanomeline Low Dose,COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,190,13
Xanomeline Low Dose,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N,3,N_and_N_pct,62,11
Xanomeline Low Dose,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N_tot,3,AEs,62,11
Xanomeline Low Dose,CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,N_pct,0.03125,N_and_N_pct,62,11
Xanomeline Low Dose,CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,N,1,N_and_N_pct,202,10
Xanomeline Low Dose,CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,N_tot,1,AEs,202,10
Xanomeline Low Dose,CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,202,10
Xanomeline Low Dose,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,75,16
Xanomeline Low Dose,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,3,AEs,75,16
Xanomeline Low Dose,CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.010416666666666666,N_and_N_pct,75,16
Xanomeline Low Dose,COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,237,13
Xanomeline Low Dose,COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,237,13
Xanomeline Low Dose,COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,237,13
Xanomeline Low Dose,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,6,N_and_N_pct,37,4
Xanomeline Low Dose,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,9,AEs,37,4
Xanomeline Low Dose,COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.0625,N_and_N_pct,37,4
Xanomeline Low Dose,CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,88,2
Xanomeline Low Dose,CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,88,2
Xanomeline Low Dose,CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,88,2
Xanomeline Low Dose,DEPRESSED MOOD,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,46,11
Xanomeline Low Dose,DEPRESSED MOOD,PSYCHIATRIC DISORDERS,N_tot,2,AEs,46,11
Xanomeline Low Dose,DEPRESSED MOOD,PSYCHIATRIC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,46,11
Xanomeline Low Dose,DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,20,3
Xanomeline Low Dose,DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,20,3
Xanomeline Low Dose,DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,20,3
Xanomeline Low Dose,DIARRHOEA,GASTROINTESTINAL DISORDERS,N,6,N_and_N_pct,23,5
Xanomeline Low Dose,DIARRHOEA,GASTROINTESTINAL DISORDERS,N_tot,8,AEs,23,5
Xanomeline Low Dose,DIARRHOEA,GASTROINTESTINAL DISORDERS,N_pct,0.0625,N_and_N_pct,23,5
Xanomeline Low Dose,DIZZINESS,NERVOUS SYSTEM DISORDERS,N,9,N_and_N_pct,76,13
Xanomeline Low Dose,DIZZINESS,NERVOUS SYSTEM DISORDERS,N_tot,14,AEs,76,13
Xanomeline Low Dose,DIZZINESS,NERVOUS SYSTEM DISORDERS,N_pct,0.09375,N_and_N_pct,76,13
Xanomeline Low Dose,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,47,5
Xanomeline Low Dose,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N_tot,2,AEs,47,5
Xanomeline Low Dose,DYSPEPSIA,GASTROINTESTINAL DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,47,5
Xanomeline Low Dose,DYSPHAGIA,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,238,5
Xanomeline Low Dose,DYSPHAGIA,GASTROINTESTINAL DISORDERS,N_tot,1,AEs,238,5
Xanomeline Low Dose,DYSPHAGIA,GASTROINTESTINAL DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,238,5
Xanomeline Low Dose,DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,89,4
Xanomeline Low Dose,DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,89,4
Xanomeline Low Dose,DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.010416666666666666,N_and_N_pct,89,4
Xanomeline Low Dose,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,63,4
Xanomeline Low Dose,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,63,4
Xanomeline Low Dose,DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.010416666666666666,N_and_N_pct,63,4
Xanomeline Low Dose,DYSURIA,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,209,9
Xanomeline Low Dose,DYSURIA,RENAL AND URINARY DISORDERS,N_tot,1,AEs,209,9
Xanomeline Low Dose,DYSURIA,RENAL AND URINARY DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,209,9
Xanomeline Low Dose,ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,N,1,N_and_N_pct,122,14
Xanomeline Low Dose,ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,N_tot,2,AEs,122,14
Xanomeline Low Dose,ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,122,14
Xanomeline Low Dose,ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,N,1,N_and_N_pct,197,14
Xanomeline Low Dose,ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,N_tot,1,AEs,197,14
Xanomeline Low Dose,ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,197,14
Xanomeline Low Dose,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N,1,N_and_N_pct,163,14
Xanomeline Low Dose,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N_tot,1,AEs,163,14
Xanomeline Low Dose,ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,163,14
Xanomeline Low Dose,ENURESIS,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,229,9
Xanomeline Low Dose,ENURESIS,RENAL AND URINARY DISORDERS,N_tot,1,AEs,229,9
Xanomeline Low Dose,ENURESIS,RENAL AND URINARY DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,229,9
Xanomeline Low Dose,EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,48,4
Xanomeline Low Dose,EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,48,4
Xanomeline Low Dose,EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.010416666666666666,N_and_N_pct,48,4
Xanomeline Low Dose,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,15,N_and_N_pct,4,3
Xanomeline Low Dose,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,24,AEs,4,3
Xanomeline Low Dose,ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.15625,N_and_N_pct,4,3
Xanomeline Low Dose,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,118,16
Xanomeline Low Dose,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,2,AEs,118,16
Xanomeline Low Dose,EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.010416666666666666,N_and_N_pct,118,16
Xanomeline Low Dose,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,2,N_and_N_pct,181,16
Xanomeline Low Dose,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,2,AEs,181,16
Xanomeline Low Dose,FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.020833333333333332,N_and_N_pct,181,16
Xanomeline Low Dose,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,5,N_and_N_pct,25,2
Xanomeline Low Dose,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,5,AEs,25,2
Xanomeline Low Dose,FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.052083333333333336,N_and_N_pct,25,2
Xanomeline Low Dose,FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,N,1,N_and_N_pct,234,12
Xanomeline Low Dose,FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,N_tot,1,AEs,234,12
Xanomeline Low Dose,FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,234,12
Xanomeline Low Dose,HEADACHE,NERVOUS SYSTEM DISORDERS,N,3,N_and_N_pct,52,13
Xanomeline Low Dose,HEADACHE,NERVOUS SYSTEM DISORDERS,N_tot,4,AEs,52,13
Xanomeline Low Dose,HEADACHE,NERVOUS SYSTEM DISORDERS,N_pct,0.03125,N_and_N_pct,52,13
Xanomeline Low Dose,HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,170,13
Xanomeline Low Dose,HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,170,13
Xanomeline Low Dose,HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,170,13
Xanomeline Low Dose,HOT FLUSH,VASCULAR DISORDERS,N,1,N_and_N_pct,156,18
Xanomeline Low Dose,HOT FLUSH,VASCULAR DISORDERS,N_tot,1,AEs,156,18
Xanomeline Low Dose,HOT FLUSH,VASCULAR DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,156,18
Xanomeline Low Dose,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,4,N_and_N_pct,78,3
Xanomeline Low Dose,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,5,AEs,78,3
Xanomeline Low Dose,HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.041666666666666664,N_and_N_pct,78,3
Xanomeline Low Dose,HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,N,1,N_and_N_pct,222,21
Xanomeline Low Dose,HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,N_tot,2,AEs,222,21
Xanomeline Low Dose,HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,222,21
Xanomeline Low Dose,HYPERTENSION,VASCULAR DISORDERS,N,2,N_and_N_pct,206,18
Xanomeline Low Dose,HYPERTENSION,VASCULAR DISORDERS,N_tot,3,AEs,206,18
Xanomeline Low Dose,HYPERTENSION,VASCULAR DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,206,18
Xanomeline Low Dose,HYPOTENSION,VASCULAR DISORDERS,N,1,N_and_N_pct,111,18
Xanomeline Low Dose,HYPOTENSION,VASCULAR DISORDERS,N_tot,1,AEs,111,18
Xanomeline Low Dose,HYPOTENSION,VASCULAR DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,111,18
Xanomeline Low Dose,INCONTINENCE,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,64,9
Xanomeline Low Dose,INCONTINENCE,RENAL AND URINARY DISORDERS,N_tot,1,AEs,64,9
Xanomeline Low Dose,INCONTINENCE,RENAL AND URINARY DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,64,9
Xanomeline Low Dose,INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,232,2
Xanomeline Low Dose,INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,232,2
Xanomeline Low Dose,INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,232,2
Xanomeline Low Dose,INFLUENZA,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,120,7
Xanomeline Low Dose,INFLUENZA,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,120,7
Xanomeline Low Dose,INFLUENZA,INFECTIONS AND INFESTATIONS,N_pct,0.010416666666666666,N_and_N_pct,120,7
Xanomeline Low Dose,IRRITABILITY,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,145,11
Xanomeline Low Dose,IRRITABILITY,PSYCHIATRIC DISORDERS,N_tot,1,AEs,145,11
Xanomeline Low Dose,IRRITABILITY,PSYCHIATRIC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,145,11
Xanomeline Low Dose,JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,65,16
Xanomeline Low Dose,JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,1,AEs,65,16
Xanomeline Low Dose,JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.010416666666666666,N_and_N_pct,65,16
Xanomeline Low Dose,LETHARGY,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,218,13
Xanomeline Low Dose,LETHARGY,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,218,13
Xanomeline Low Dose,LETHARGY,NERVOUS SYSTEM DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,218,13
Xanomeline Low Dose,LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,34,7
Xanomeline Low Dose,LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,34,7
Xanomeline Low Dose,LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.010416666666666666,N_and_N_pct,34,7
Xanomeline Low Dose,MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,81,2
Xanomeline Low Dose,MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,81,2
Xanomeline Low Dose,MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,81,2
Xanomeline Low Dose,MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N,1,N_and_N_pct,221,23
Xanomeline Low Dose,MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N_tot,2,AEs,221,23
Xanomeline Low Dose,MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",N_pct,0.010416666666666666,N_and_N_pct,221,23
Xanomeline Low Dose,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N,1,N_and_N_pct,35,9
Xanomeline Low Dose,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N_tot,1,AEs,35,9
Xanomeline Low Dose,MICTURITION URGENCY,RENAL AND URINARY DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,35,9
Xanomeline Low Dose,MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,157,8
Xanomeline Low Dose,MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,1,AEs,157,8
Xanomeline Low Dose,MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,157,8
Xanomeline Low Dose,MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,1,N_and_N_pct,57,8
Xanomeline Low Dose,MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,2,AEs,57,8
Xanomeline Low Dose,MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,57,8
Xanomeline Low Dose,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N,2,N_and_N_pct,112,6
Xanomeline Low Dose,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N_tot,4,AEs,112,6
Xanomeline Low Dose,MYOCARDIAL INFARCTION,CARDIAC DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,112,6
Xanomeline Low Dose,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,29,4
Xanomeline Low Dose,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,29,4
Xanomeline Low Dose,NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.010416666666666666,N_and_N_pct,29,4
Xanomeline Low Dose,NASAL MUCOSA BIOPSY,INVESTIGATIONS,N,1,N_and_N_pct,58,14
Xanomeline Low Dose,NASAL MUCOSA BIOPSY,INVESTIGATIONS,N_tot,1,AEs,58,14
Xanomeline Low Dose,NASAL MUCOSA BIOPSY,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,58,14
Xanomeline Low Dose,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N,4,N_and_N_pct,53,7
Xanomeline Low Dose,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N_tot,9,AEs,53,7
Xanomeline Low Dose,NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,N_pct,0.041666666666666664,N_and_N_pct,53,7
Xanomeline Low Dose,NAUSEA,GASTROINTESTINAL DISORDERS,N,3,N_and_N_pct,71,5
Xanomeline Low Dose,NAUSEA,GASTROINTESTINAL DISORDERS,N_tot,5,AEs,71,5
Xanomeline Low Dose,NAUSEA,GASTROINTESTINAL DISORDERS,N_pct,0.03125,N_and_N_pct,71,5
Xanomeline Low Dose,NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,94,14
Xanomeline Low Dose,NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,N_tot,2,AEs,94,14
Xanomeline Low Dose,NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,94,14
Xanomeline Low Dose,OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,2,N_and_N_pct,128,2
Xanomeline Low Dose,OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,128,2
Xanomeline Low Dose,OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.020833333333333332,N_and_N_pct,128,2
Xanomeline Low Dose,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,105,2
Xanomeline Low Dose,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,105,2
Xanomeline Low Dose,OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,105,2
Xanomeline Low Dose,ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,90,7
Xanomeline Low Dose,ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,90,7
Xanomeline Low Dose,ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,N_pct,0.010416666666666666,N_and_N_pct,90,7
Xanomeline Low Dose,PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,83,2
Xanomeline Low Dose,PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,83,2
Xanomeline Low Dose,PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,83,2
Xanomeline Low Dose,PALPITATIONS,CARDIAC DISORDERS,N,2,N_and_N_pct,123,6
Xanomeline Low Dose,PALPITATIONS,CARDIAC DISORDERS,N_tot,2,AEs,123,6
Xanomeline Low Dose,PALPITATIONS,CARDIAC DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,123,6
Xanomeline Low Dose,PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,203,13
Xanomeline Low Dose,PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,203,13
Xanomeline Low Dose,PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,203,13
Xanomeline Low Dose,PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,30,4
Xanomeline Low Dose,PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,1,AEs,30,4
Xanomeline Low Dose,PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.010416666666666666,N_and_N_pct,30,4
Xanomeline Low Dose,PNEUMONIA,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,59,7
Xanomeline Low Dose,PNEUMONIA,INFECTIONS AND INFESTATIONS,N_tot,2,AEs,59,7
Xanomeline Low Dose,PNEUMONIA,INFECTIONS AND INFESTATIONS,N_pct,0.010416666666666666,N_and_N_pct,59,7
Xanomeline Low Dose,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,23,N_and_N_pct,36,3
Xanomeline Low Dose,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,35,AEs,36,3
Xanomeline Low Dose,PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.23958333333333334,N_and_N_pct,36,3
Xanomeline Low Dose,PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,31,3
Xanomeline Low Dose,PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,4,AEs,31,3
Xanomeline Low Dose,PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,31,3
Xanomeline Low Dose,PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,41,2
Xanomeline Low Dose,PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,41,2
Xanomeline Low Dose,PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,41,2
Xanomeline Low Dose,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,13,N_and_N_pct,43,3
Xanomeline Low Dose,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,18,AEs,43,3
Xanomeline Low Dose,RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.13541666666666666,N_and_N_pct,43,3
Xanomeline Low Dose,RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,2,N_and_N_pct,10,3
Xanomeline Low Dose,RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,10,3
Xanomeline Low Dose,RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,10,3
Xanomeline Low Dose,RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,139,3
Xanomeline Low Dose,RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,139,3
Xanomeline Low Dose,RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,139,3
Xanomeline Low Dose,RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,N,1,N_and_N_pct,95,5
Xanomeline Low Dose,RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,N_tot,2,AEs,95,5
Xanomeline Low Dose,RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,95,5
Xanomeline Low Dose,RESTLESSNESS,PSYCHIATRIC DISORDERS,N,1,N_and_N_pct,219,11
Xanomeline Low Dose,RESTLESSNESS,PSYCHIATRIC DISORDERS,N_tot,2,AEs,219,11
Xanomeline Low Dose,RESTLESSNESS,PSYCHIATRIC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,219,11
Xanomeline Low Dose,RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N,1,N_and_N_pct,74,4
Xanomeline Low Dose,RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_tot,2,AEs,74,4
Xanomeline Low Dose,RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",N_pct,0.010416666666666666,N_and_N_pct,74,4
Xanomeline Low Dose,SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,60,2
Xanomeline Low Dose,SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,2,AEs,60,2
Xanomeline Low Dose,SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,60,2
Xanomeline Low Dose,SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N,2,N_and_N_pct,66,8
Xanomeline Low Dose,SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_tot,2,AEs,66,8
Xanomeline Low Dose,SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,66,8
Xanomeline Low Dose,SINUS BRADYCARDIA,CARDIAC DISORDERS,N,7,N_and_N_pct,115,6
Xanomeline Low Dose,SINUS BRADYCARDIA,CARDIAC DISORDERS,N_tot,10,AEs,115,6
Xanomeline Low Dose,SINUS BRADYCARDIA,CARDIAC DISORDERS,N_pct,0.07291666666666667,N_and_N_pct,115,6
Xanomeline Low Dose,SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,186,3
Xanomeline Low Dose,SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,2,AEs,186,3
Xanomeline Low Dose,SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,186,3
Xanomeline Low Dose,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,6,N_and_N_pct,96,3
Xanomeline Low Dose,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,13,AEs,96,3
Xanomeline Low Dose,SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.0625,N_and_N_pct,96,3
Xanomeline Low Dose,SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,2,N_and_N_pct,67,16
Xanomeline Low Dose,SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,2,AEs,67,16
Xanomeline Low Dose,SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.020833333333333332,N_and_N_pct,67,16
Xanomeline Low Dose,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N,3,N_and_N_pct,106,13
Xanomeline Low Dose,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N_tot,5,AEs,106,13
Xanomeline Low Dose,SOMNOLENCE,NERVOUS SYSTEM DISORDERS,N_pct,0.03125,N_and_N_pct,106,13
Xanomeline Low Dose,STUPOR,NERVOUS SYSTEM DISORDERS,N,1,N_and_N_pct,151,13
Xanomeline Low Dose,STUPOR,NERVOUS SYSTEM DISORDERS,N_tot,1,AEs,151,13
Xanomeline Low Dose,STUPOR,NERVOUS SYSTEM DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,151,13
Xanomeline Low Dose,SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,68,2
Xanomeline Low Dose,SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,68,2
Xanomeline Low Dose,SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,68,2
Xanomeline Low Dose,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N,1,N_and_N_pct,188,6
Xanomeline Low Dose,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_tot,2,AEs,188,6
Xanomeline Low Dose,SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,188,6
Xanomeline Low Dose,SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,N,1,N_and_N_pct,198,6
Xanomeline Low Dose,SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,N_tot,2,AEs,198,6
Xanomeline Low Dose,SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,198,6
Xanomeline Low Dose,SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,223,2
Xanomeline Low Dose,SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,223,2
Xanomeline Low Dose,SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,223,2
Xanomeline Low Dose,SYNCOPE,NERVOUS SYSTEM DISORDERS,N,5,N_and_N_pct,146,13
Xanomeline Low Dose,SYNCOPE,NERVOUS SYSTEM DISORDERS,N_tot,7,AEs,146,13
Xanomeline Low Dose,SYNCOPE,NERVOUS SYSTEM DISORDERS,N_pct,0.052083333333333336,N_and_N_pct,146,13
Xanomeline Low Dose,TINNITUS,EAR AND LABYRINTH DISORDERS,N,1,N_and_N_pct,204,20
Xanomeline Low Dose,TINNITUS,EAR AND LABYRINTH DISORDERS,N_tot,1,AEs,204,20
Xanomeline Low Dose,TINNITUS,EAR AND LABYRINTH DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,204,20
Xanomeline Low Dose,TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,N,2,N_and_N_pct,116,13
Xanomeline Low Dose,TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,N_tot,3,AEs,116,13
Xanomeline Low Dose,TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,116,13
Xanomeline Low Dose,ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N,1,N_and_N_pct,227,2
Xanomeline Low Dose,ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_tot,1,AEs,227,2
Xanomeline Low Dose,ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,N_pct,0.010416666666666666,N_and_N_pct,227,2
Xanomeline Low Dose,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,28,7
Xanomeline Low Dose,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_tot,2,AEs,28,7
Xanomeline Low Dose,UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.010416666666666666,N_and_N_pct,28,7
Xanomeline Low Dose,URINE ANALYSIS ABNORMAL,INVESTIGATIONS,N,1,N_and_N_pct,97,14
Xanomeline Low Dose,URINE ANALYSIS ABNORMAL,INVESTIGATIONS,N_tot,2,AEs,97,14
Xanomeline Low Dose,URINE ANALYSIS ABNORMAL,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,97,14
Xanomeline Low Dose,URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N,1,N_and_N_pct,56,3
Xanomeline Low Dose,URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_tot,3,AEs,56,3
Xanomeline Low Dose,URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,56,3
Xanomeline Low Dose,VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N,2,N_and_N_pct,158,6
Xanomeline Low Dose,VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_tot,4,AEs,158,6
Xanomeline Low Dose,VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,N_pct,0.020833333333333332,N_and_N_pct,158,6
Xanomeline Low Dose,VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",N,1,N_and_N_pct,121,19
Xanomeline Low Dose,VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",N_tot,1,AEs,121,19
Xanomeline Low Dose,VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",N_pct,0.010416666666666666,N_and_N_pct,121,19
Xanomeline Low Dose,VERTIGO,EAR AND LABYRINTH DISORDERS,N,1,N_and_N_pct,124,20
Xanomeline Low Dose,VERTIGO,EAR AND LABYRINTH DISORDERS,N_tot,1,AEs,124,20
Xanomeline Low Dose,VERTIGO,EAR AND LABYRINTH DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,124,20
Xanomeline Low Dose,VIRAL INFECTION,INFECTIONS AND INFESTATIONS,N,1,N_and_N_pct,132,7
Xanomeline Low Dose,VIRAL INFECTION,INFECTIONS AND INFESTATIONS,N_tot,1,AEs,132,7
Xanomeline Low Dose,VIRAL INFECTION,INFECTIONS AND INFESTATIONS,N_pct,0.010416666666666666,N_and_N_pct,132,7
Xanomeline Low Dose,VISION BLURRED,EYE DISORDERS,N,1,N_and_N_pct,152,10
Xanomeline Low Dose,VISION BLURRED,EYE DISORDERS,N_tot,1,AEs,152,10
Xanomeline Low Dose,VISION BLURRED,EYE DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,152,10
Xanomeline Low Dose,VOMITING,GASTROINTESTINAL DISORDERS,N,4,N_and_N_pct,54,5
Xanomeline Low Dose,VOMITING,GASTROINTESTINAL DISORDERS,N_tot,5,AEs,54,5
Xanomeline Low Dose,VOMITING,GASTROINTESTINAL DISORDERS,N_pct,0.041666666666666664,N_and_N_pct,54,5
Xanomeline Low Dose,WEIGHT DECREASED,INVESTIGATIONS,N,1,N_and_N_pct,114,14
Xanomeline Low Dose,WEIGHT DECREASED,INVESTIGATIONS,N_tot,2,AEs,114,14
Xanomeline Low Dose,WEIGHT DECREASED,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,114,14
Xanomeline Low Dose,WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,N,1,N_and_N_pct,98,14
Xanomeline Low Dose,WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,N_tot,2,AEs,98,14
Xanomeline Low Dose,WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,N_pct,0.010416666666666666,N_and_N_pct,98,14
Xanomeline Low Dose,WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,N,1,N_and_N_pct,125,6
Xanomeline Low Dose,WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,N_tot,2,AEs,125,6
Xanomeline Low Dose,WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,N_pct,0.010416666666666666,N_and_N_pct,125,6
Xanomeline Low Dose,WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N,1,N_and_N_pct,230,16
Xanomeline Low Dose,WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_tot,2,AEs,230,16
Xanomeline Low Dose,WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",N_pct,0.010416666666666666,N_and_N_pct,230,16
